Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Transl Res. 2012 Jun;159(6):421-9. doi: 10.1016/j.trsl.2011.12.007. Epub 2012 Jan 10.
More than 130 million people worldwide are chronically infected with the hepatitis C virus (HCV), which can lead to cirrhosis, liver failure, and hepatocellular carcinoma. Although recently approved HCV NS3-4A protease inhibitors significantly improve treatment response rates, current HCV treatment is still frequently limited by side effects and by the low genetic barrier to viral resistance against direct-acting antiviral agents. A complementary strategy is to target the host cellular factors that support the HCV life cycle. Several studies, including RNA interference screens, demonstrated that HCV depends on dozens, if not hundreds, of cellular proteins to complete its life cycle. A better understanding of the interactions between HCV proteins and host factors may help to identify host targets for antiviral therapy. In this review, we highlight some of the host factors that are particularly attractive targets for the treatment of HCV.
全球有超过 1.3 亿人慢性感染丙型肝炎病毒（HCV），这可能导致肝硬化、肝衰竭和肝细胞癌。尽管最近批准的 HCV NS3-4A 蛋白酶抑制剂显著提高了治疗反应率，但目前的 HCV 治疗仍然经常受到副作用和抗病毒药物的低遗传耐药性的限制。一种补充策略是针对支持 HCV 生命周期的宿主细胞因子。包括 RNA 干扰筛选在内的几项研究表明，HCV 依赖数十种甚至数百种细胞蛋白来完成其生命周期。更好地了解 HCV 蛋白与宿主因子之间的相互作用可能有助于确定宿主抗病毒治疗的靶标。在这篇综述中，我们重点介绍了一些特别有吸引力的宿主因子，它们是 HCV 治疗的靶标。
